What type of study is this?

September 5, 2025Open Access

Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Key Points

FOLFOX and FOLFIRI showed distinct efficacy in altering treatment outcomes for metastatic colorectal cancer patients.
The study included RAS and BRAF mutation profiles, highlighting their impact on treatment effectiveness.
Observational analysis of chemotherapy regimens in RAS/BRAF mutant patients aims to define treatment standards.
Reveals the need for tailored chemotherapy strategies, supporting better outcomes in colorectal cancer management.

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings. Despite advances in treatment, the optimal chemotherapy backbone combined with bevacizumab in RAS/BRAF-mutant metastatic CRC remains unclear. Our study aimed to investigate the best chemotherapy backbone in this patient group.

AI에게 질문

Bookmark

View Full Paper